NeurologyLive Friday 5 — August 21, 2020
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Marwan Sabbagh, MD: Outlook of Aducanumab in Alzheimer Disease
The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed the potential of aducanumab and the amyloid theory in patients with Alzheimer disease.
2: EVT Shows Benefit in Large Vessel Occlusion Stroke Despite Late Presentation
Endovascular treatment may benefit patients with emergent large vessel occlusion and target mismatch profiles regardless of the time from onset.
3: Lara Jehi, MD: Cost-Effectiveness of Epilepsy Surgery
The chief research officer and epilepsy specialist at Cleveland Clinic detailed her most recent findings on the cost-effectiveness of epilepsy surgery for drug-resistant temporal lobe epilepsy.
4: Laryngeal Dysfunction May Distinguish Multiple System Atrophy From Parkinson Disease
The presence of laryngeal movement disorders—identified in 93% of the MSA group—may serve as a diagnostic biomarker of MSA independent of phenotype, disease duration, or patient age.
5: Insights: A 16-Year-Old Male With Idiopathic Generalized Epilepsy
Michael R. Sperling, MD, provides an overview of a case of a 16-year-old male diagnosed with idiopathic generalized epilepsy.
